Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
Authors' conclusion
Evidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged.
Study context
- Population
- Studies of assays reflecting IFN-I pathway activation in RMDs (most studied: Systemic lupus erythematosus (SLE), RA, myositis, SSc, primary Sjögren's syndrome)studies selected of 366 screened
- Participants
- 276 studies
- Outcome
- Use of IFN-I assays in diagnosis, disease activity monitoring, prognosis, response to treatment and responsiveness to change
Methodological detailsthree databases, informing EULAR points to consider
- Three databases
- Informing EULAR points to consider
Main finding
As reported in the abstract
Studies by clinical application of IFN-I pathway assays
- Disease diagnosis (studies)
- 188
- Assessment of disease activity (studies)
- 122
- Prognosis (studies)
- 20
- Response to treatment (studies)
- 23
- Assay responsiveness (studies)
- 59
Original publication
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open. Published 7 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →